Key Highlights

  • Rapid Micro Biosystems (NASDAQ:RPID) reported third-quarter Revenue of USD 9.5 million, up 21.6% from USD 7.8 million a year earlier.
  • Gross Margin reached a quarterly record of 25.2%, or USD 2.4 million, compared with 8.9% a year earlier.
  • The net loss was USD 11.3 million, or USD 0.23 per share, against USD 11.5 million, or USD 0.26 per share, and the adjusted EBITDA loss narrowed to USD 7.9 million.
  • The company agreed to be acquired by Merck KGaA, Darmstadt, Germany, withdrew 2026 guidance, and will delay its Form 10-Q.

Seven Placements and a Record Margin in the Third Quarter

Rapid Micro Biosystems (NASDAQ:RPID) released third-quarter results on November 16, 2026. The Lexington, Massachusetts company sells Growth Direct, an automated system that replaces manual microbial quality control testing in pharmaceutical Manufacturing of products such as biologics, vaccines and sterile injectables. Revenue grew 21.6% to USD 9.5 million, with product revenue up 24.9% to USD 6.5 million and service revenue up 14.9% to USD 3.0 million. The company placed seven systems and completed 12 validations, against five placements and four validations a year earlier. Recurring Revenue rose 6.9% to USD 5.2 million. The chief executive said the margin initiatives are working, and described the Partnership with the acquirer as built over the past 18 months around modernizing quality control workflows for customers.

Gross Margin Widens While Operating Costs Edge Up

Cost of revenue was flat at USD 7.1 million, so gross margin rose to USD 2.4 million, or 25.2%. Product gross margin improved by 19 points to 12%, and service gross margin rose by 14 points to 54%. Operating expenses increased 8.1% to USD 13.0 million, including a USD 0.7 million restructuring charge from an efficiency program announced in August 2026. General and administrative expense rose 12.2%, sales and Marketing rose 4.3% and Research and Development fell 15.8%. The operating loss narrowed to USD 10.6 million from USD 11.4 million. Nine-month revenue was USD 25.6 million against USD 22.3 million, with a net loss of USD 38.5 million, or USD 0.79 per share, versus USD 34.6 million, or USD 0.78. Interest expense rose to USD 0.6 million in the quarter from USD 0.4 million.

Merck KGaA Agreement Overrides the Usual Reporting Calendar

The company said it signed a definitive agreement under which Merck KGaA, Darmstadt, Germany, will acquire all outstanding shares through a tender offer that has not yet begun. Because of the deal, it will not host a conference call, has withdrawn its full-year 2026 guidance, and will delay its Quarterly Report on Form 10-Q, intending to file within the extension period allowed by the SEC. Cash, cash equivalents and short-term investments were about USD 7 million at September 30, 2026, down from USD 38.3 million at year-end 2025, which is calculated from the balance sheet. Notes payable were USD 19.2 million, and stockholders Equity was USD 8.8 million, down from USD 33.2 million at year-end 2025. Inventory was USD 19.7 million and Accounts Receivable rose to USD 7.7 million.

Where Things Stand

The revenue and margin gains are real, but the pending Acquisition now frames the story. Rapid Micro Biosystems (NASDAQ:RPID) grew sales 21.6%, reached a record gross margin of 25.2% and trimmed its adjusted EBITDA loss to USD 7.9 million, yet cash fell to about USD 7 million. Merck KGaA, Darmstadt, Germany, has agreed to acquire the company, and guidance is withdrawn. Next steps are the start of the tender offer and the delayed quarterly filing, which will add detail on liquidity.